Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Dapagliflozin and metformin hydrochloride

Also listed by the FDA as: dapagliflozin / metformin hydrochloride · dapagliflozin propanediol / metformin hydrochloride

Drug class: Sodium-Glucose Cotransporter 2 Inhibitor

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Dapagliflozin and metformin hydrochloride key facts

Drug class
Sodium-Glucose Cotransporter 2 Inhibitor
Used for
XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$0.8146 per tablet (dapagliflozin 10 mg · metformin hydrochloride 1000 mg; NADAC)
Latest FDA recall
March 15, 2021 (Class II)

Sources: FDA label (August 11, 2026); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Dapagliflozin and metformin hydrochloride used for?
The FDA-approved label (Xigduo XR, AstraZeneca Pharmaceuticals LP, August 11, 2026) says: “XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Dapagliflozin and metformin hydrochloride?
The “Adverse Reactions” section of the FDA label (Xigduo XR, AstraZeneca Pharmaceuticals LP, August 11, 2026) begins: “The following important adverse reactions are described below and elsewhere in the labeling: • Lactic Acidosis [see Boxed Warning and Warnings and Precautions (5.1)] • Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis [see Warnings and Precautions (5.2)] • Volume Depletion [see Warnings and Precautions (5.3)] • Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections [see Warnings and Precautions (5.4)] • Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.5)] • Vitamin B 12 Deficiency [see Warnings and Precautions (5.6)] • Adverse reactions reported in >5% of patients treated with XIGDUO XR were female genital mycotic infection, nasopharyngitis, urinary tract infection, diarrhea, and headache.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Dapagliflozin and metformin hydrochloride?
The “Drug Interactions” section of the FDA label (Xigduo XR, AstraZeneca Pharmaceuticals LP, August 11, 2026) begins: “Table 6: Clinically Relevant Interactions with XIGDUO XR Carbonic Anhydrase Inhibitors Clinical Impact Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with XIGDUO XR may increase the risk for lactic acidosis. Intervention Consider more frequent monitoring of these patients.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Dapagliflozin and metformin hydrochloride have a boxed warning?
Yes. The FDA label for Xigduo XR has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Dapagliflozin and metformin hydrochloride?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Dapagliflozin and metformin hydrochloride been recalled?
FDA enforcement reports list 2 recalls of products of this medicine; the newest started March 15, 2021 (Class II). A recall usually concerns specific lots, not every product.
Who makes Dapagliflozin and metformin hydrochloride?
10 companies list prescription products of Dapagliflozin and metformin hydrochloride in the FDA NDC Directory, including AstraZeneca Pharmaceuticals LP, Novadoz Pharmaceuticals LLC and Macleods Pharmaceuticals Limited.

What Dapagliflozin and metformin hydrochloride is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of …

— FDA label: Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (tablet, film coated, extended release, oral), Xigduo XR, AstraZeneca Pharmaceuticals LP; it covers 5 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 10 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Read it on the full label →

10 of 10 FDA labels for this medicine have a boxed warning.

Dapagliflozin and metformin hydrochloride boxed warning: what the label says

Quoted from the boxed warning of the FDA-approved label.

WARNING: LACTIC ACIDOSIS

  • Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by non‑specific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.
Read more of this section

Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1)].

  • Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment and mitochondrial diseases [see Warnings and Precautions (5.1)].
  • Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the full prescribing information [see Dosage and Administration (2.1 and 2.4), Contraindications (4), Warnings and Precautions (5.1), Drug Interactions (7), and Use in Specific Populations (8.6, 8.7)].
  • If metformin-associated lactic acidosis is suspected, immediately discontinue XIGDUO XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)]. WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning.
  • Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. (5.1)
  • Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. (5.1)
  • If lactic acidosis is suspected, discontinue XIGDUO XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)

— FDA label: Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026. Read the full label on DailyMed →

Dapagliflozin and metformin hydrochloride side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following important adverse reactions are described below and elsewhere in the labeling:

  • Lactic Acidosis [see Boxed Warning and Warnings and Precautions (5.1)]
  • Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis [see Warnings and Precautions (5.2)]
  • Volume Depletion [see Warnings and Precautions (5.3)]
  • Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections [see Warnings and Precautions (5.4)]
  • Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.5)]
  • Vitamin B 12 Deficiency [see Warnings and Precautions (5.6)]
  • Adverse reactions reported in >5% of patients treated with XIGDUO XR were female genital mycotic infection, nasopharyngitis, urinary tract infection, diarrhea, and headache.
Read more of this section

(6.1)

  • Adverse reactions reported in >5% of patients treated with metformin extended-release are: diarrhea and nausea/vomiting. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Clinical Trials with Metformin HCl Extended-Release in Adults with Type 2 Diabetes Mellitus In placebo-controlled monotherapy trials of metformin HCl extended-release, diarrhea and nausea/vomiting were reported in >5% of metformin-treated patients and more commonly than in placebo-treated patients (9.6% versus 2.6% for diarrhea and 6.5% versus 1.5% for nausea/vomiting). Diarrhea led to discontinuation of study medication in 0.6% of the patients treated with metformin HCl extended-release. Clinical Trials with Dapagliflozin in Adults Dapagliflozin Dapagliflozin has been evaluated in clinical trials in adult and pediatric patients 10 years of age and older with type 2 diabetes mellitus, in adult patients with heart failure, and in adult patients with chronic kidney disease. The overall safety profile of dapagliflozin was consistent across the studied indications. No new adverse reactions were identified in the DAPA-HF, DELIVER and DAPA-CKD trials. Pools of Placebo-Controlled Clinical Trials for Glycemic Control in Adults Pool of 8 Placebo-Controlled Adult Trials for Dapagliflozin and Metformin HCl for Glycemic Control Data from a prespecified pool of adult patients from 8 short-term, placebo-controlled trials of dapagliflozin coadministered with metformin HCl immediate- or extended-release was used to evaluate safety. This pool included several add-on trials (metformin HCl alone and in combination with a dipeptidyl peptidase-4 [DPP4] inhibitor and metformin HCl, or insulin and metformin HCl, 2 initial combination with metformin HCl trials, and 2 trials of patients with CVD and type 2 diabetes mellitus who received their usual treatment [with metformin HCl as background therapy]). For trials that included background therapy with and without metformin HCl, only patients who received metformin HCl were included in the 8-trial placebo-controlled pool. Across these 8 trials, 983 patients were treated once daily with dapagliflozin 10 mg and metformin HCl, and 1185 were treated with placebo and metformin HCl. These 8 trials provide a mean duration of exposure of 23 weeks. The mean age of the population was 57 years and 2% were older than 75 years.
Table from the label
PlaceboDapagliflozin5 mgDapagliflozin10 mg
Add-on to Metformin HCl (24 weeks)N=137N=137N=135
Severe [n (%)]000
Glucose < 54 mg/dL [n (%)]000
Add-on to DPP4 inhibitor (with or without Metformin HCl) (24 weeks)N=226–N=225
Severe [n (%)]0–1 (0.4)
Glucose < 54 mg/dL [n (%)]1 (0.4)–1 (0.4)
Add-on to Insulin with or without other OADsOAD = oral antidiabetic therapy. (24 weeks)N=197N=212N=196
Severe [n (%)]1 (0.5)2 (0.9)2 (1.0)
Glucose < 54 mg/dL [n (%)]43 (21.8)55 (25.9)45 (23.0)

— FDA label: Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026. This is part of the section. Read the full label on DailyMed →

Dapagliflozin and metformin hydrochloride drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

Table 6: Clinically Relevant Interactions with XIGDUO XR Carbonic Anhydrase Inhibitors Clinical Impact Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with XIGDUO XR may increase the risk for lactic acidosis. Intervention Consider more frequent monitoring of these patients.

Read more of this section

Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Intervention Consider the benefits and risks of concomitant use. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. Intervention Warn patients against excessive alcohol intake while receiving XIGDUO XR. Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when XIGDUO XR is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.5)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Drugs Affecting Glycemic Control Clinical Impact Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. Intervention When such drugs are administered to a patient receiving XIGDUO XR, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving XIGDUO XR, observe the patient closely for hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during XIGDUO XR initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Intervention Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control. Interference with 1,5-anhydroglucitol (1,5-AG) Assay Clinical Impact Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Intervention Monitoring glycemic control with 1,5-AG assay is not recommended. Use alternative methods to monitor glycemic control.

  • Carbonic anhydrase inhibitors: May increase risk of lactic acidosis. Consider more frequent monitoring. (7)
  • Drugs that reduce metformin clearance: May increase risk of lactic acidosis. Consider benefits and risks of concomitant use.

— FDA label: Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026. This is part of the section. Read the full label on DailyMed →

Dapagliflozin and metformin hydrochloride dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

  • Assess renal function prior to initiating and then as clinically indicated. (2.1)
  • Assess volume status and correct volume depletion before initiating. (2.1)
  • Individualize the starting dosage based on the patient’s current treatment. (2.3)
  • Administer orally once daily in the morning with food. (2.2)
  • To improve glycemic control, for patients aged 10 years and older not already taking dapagliflozin, the recommended starting dosage for dapagliflozin is 5 mg once daily.
Read more of this section

(2.3)

  • For indications in adults related to heart failure and chronic kidney disease the recommended dosage of dapagliflozin is 10 mg once daily. (2.3)
  • Do not exceed a daily dosage of 10 mg dapagliflozin/2,000 mg metformin HCl extended-release. (2.3)
  • See Full Prescribing Information for dosage recommendations in patients with renal impairment. (2.4)
  • XIGDUO XR may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. (2.5)
  • Withhold XIGDUO XR for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. (2.6) 2.1 Testing Prior to Initiation of XIGDUO XR
  • Assess renal function prior to initiating XIGDUO XR and then as clinically indicated [see Warnings and Precautions (5.1, 5.3)].
  • Assess volume status. In patients with volume depletion, correct this condition before initiating XIGDUO XR [see Warnings and Precautions (5.3) and Use in Specific Populations (8.5, 8.6)]. 2.2 Recommended Administration
  • Take XIGDUO XR orally once daily in the morning with food.
  • Swallow XIGDUO XR tablets whole and never crush, cut, or chew. 2.3 Recommended Dosage
  • Individualize the starting dosage of XIGDUO XR based upon the patient’s current regimen. Patients taking an evening dosage of metformin HCl extended‑release should skip their last dose before starting XIGDUO XR.
  • To improve glycemic control in adults and pediatric patients aged 10 years and older not already taking: ∘ Dapagliflozin: the recommended starting dosage of dapagliflozin in XIGDUO XR is 5 mg orally once daily. ∘ Metformin HCl extended‑release: the recommended starting dosage of metformin HCl extended‑release in XIGDUO XR is 500 mg orally once daily.
  • For XIGDUO XR indications in adults related to heart failure and chronic kidney disease, the recommended dosage of dapagliflozin in XIGDUO XR is 10 mg orally once daily.
  • For all XIGDUO XR indications, the dosage may be adjusted based on effectiveness and tolerability. The maximum recommended daily dosage of dapagliflozin is 10 mg and 2,000 mg of metformin HCl extended‑release, with gradual dosage escalation to reduce gastrointestinal adverse reactions with metformin HCl [see Adverse Reactions (6.1)]. 2.4 Recommended Dosage in Patients with Renal Impairment
  • The recommended dosage of XIGDUO XR in patients with an estimated glomerular filtration rate (eGFR) greater than or equal to 45 mL/min/1.73 m 2 is the same as the recommended dosage in patients with normal renal function.
  • Initiation of XIGDUO XR is not recommended in patients with an eGFR between 30 and 45 mL/min/1.73 m 2.

— FDA label: Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026. This is part of the section. Read the full label on DailyMed →

Dapagliflozin and metformin hydrochloride in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Based on animal data showing adverse renal effects, XIGDUO XR is not recommended during the second and third trimesters of pregnancy. Limited data with XIGDUO XR or dapagliflozin in pregnant women are not sufficient to determine drug‑associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk (see Data).

Read more of this section

There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations). In animal studies, adverse renal pelvic and tubule dilatations, that were not fully reversible, were observed in rats when dapagliflozin was administered during a period of renal development corresponding to the late second and third trimesters of human pregnancy, at all doses tested; the lowest of which provided an exposure 15-times the 10 mg clinical dose (see Data). The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes with a HbA1c greater than 7% and has been reported to be as high as 20 to 25% in women with HbA1c greater than 10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryofetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data Human Data Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups. Animal Data Dapagliflozin Dapagliflozin dosed directly to juvenile rats from postnatal day (PND) 21 until PND 90 at doses of 1, 15, or 75 mg/kg/day, increased kidney weights and increased the incidence of renal pelvic and tubular dilatations at all dose levels. Exposure at the lowest dose tested was 15-times the 10 mg clinical dose (based on AUC). The renal pelvic and tubular dilatations observed in juvenile animals did not fully reverse within a 1-month recovery period. In a prenatal and postnatal development study, dapagliflozin was administered to maternal rats from gestation day 6 through lactation day 21 at doses of 1, 15, or 75 mg/kg/day, and pups were indirectly exposed in utero and throughout lactation. Increased incidence or severity of renal pelvic dilatation was observed in 21-day-old pups offspring of treated dams at 75 mg/kg/day (maternal and pup dapagliflozin exposures were 1415-times and 137-times, respectively, the human values at the 10 mg clinical dose, based on AUC).

— FDA label: Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026. This is part of the section. Read the full label on DailyMed →

When Dapagliflozin and metformin hydrochloride should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

XIGDUO XR is contraindicated in patients with:

  • Severe renal impairment (eGFR below 30 mL/min/1.73 m 2) or end-stage renal disease [see Warnings and Precautions (5.1)].
  • History of a serious hypersensitivity reaction to dapagliflozin, metformin HCl, or any of the excipients in XIGDUO XR. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with dapagliflozin [see Adverse Reactions (6.1)].
Read more of this section
  • Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin [see Warnings and Precautions (5.1) and Warnings and Precautions (5.2)].
  • Severe renal impairment (eGFR below 30 mL/min/1.73 m 2) or end-stage renal disease. (4)
  • History of serious hypersensitivity to dapagliflozin, metformin HCl, or any of the excipients in XIGDUO XR. (4)
  • Metabolic acidosis, including diabetic ketoacidosis. (4)

— FDA label: Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026. Read the full label on DailyMed →

Dapagliflozin and metformin hydrochloride overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

Dapagliflozin In the event of an overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. The removal of dapagliflozin by hemodialysis has not been studied. Metformin HCl Overdose of metformin HCl has occurred, including ingestion of amounts >50 grams. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see Warnings and Precautions (5.1)].

Read more of this section

Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.

— FDA label: Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsTablet, film coated, extended release · Tablet, extended release
RouteOral
Prescription products37 in the FDA NDC Directory
Brand namesXigduo XR

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Dapagliflozin and metformin hydrochloride, by strength and form
Strength and formGeneric or brandPharmacies pay
dapagliflozin 10 mg · metformin hydrochloride 1000 mg
tablet, extended release
Generic $0.8146 per tablet
dapagliflozin 10 mg · metformin hydrochloride 1000 mg
tablet, film coated, extended release
Generic $0.8146 per tablet
dapagliflozin 10 mg · metformin hydrochloride 500 mg
tablet, extended release
Generic $0.7588 per tablet
dapagliflozin 10 mg · metformin hydrochloride 500 mg
tablet, film coated, extended release
Generic $0.7588 per tablet
dapagliflozin 5 mg · metformin hydrochloride 1000 mg
tablet, extended release
Generic $0.4871 per tablet
dapagliflozin 5 mg · metformin hydrochloride 1000 mg
tablet, film coated, extended release
Generic $0.4871 per tablet
dapagliflozin 5 mg · metformin hydrochloride 500 mg
tablet, extended release
Generic $0.7060 per tablet
dapagliflozin 5 mg · metformin hydrochloride 500 mg
tablet, film coated, extended release
Generic $0.7060 per tablet
dapagliflozin propanediol 10 mg · metformin hydrochloride 1000 mg
tablet, film coated, extended release
Generic $0.8146 per tablet
dapagliflozin propanediol 10 mg · metformin hydrochloride 1000 mg
tablet, film coated, extended release
Brand: Xigduo XR $19.20 per tablet
dapagliflozin propanediol 10 mg · metformin hydrochloride 500 mg
tablet, film coated, extended release
Brand: Xigduo XR $19.23 per tablet
dapagliflozin propanediol 2.5 mg · metformin hydrochloride 1000 mg
tablet, film coated, extended release
Brand: Xigduo XR $9.61 per tablet
dapagliflozin propanediol 5 mg · metformin hydrochloride 1000 mg
tablet, film coated, extended release
Generic $0.4871 per tablet
dapagliflozin propanediol 5 mg · metformin hydrochloride 1000 mg
tablet, film coated, extended release
Brand: Xigduo XR $9.59 per tablet
dapagliflozin propanediol 5 mg · metformin hydrochloride 500 mg
tablet, film coated, extended release
Brand: Xigduo XR $19.18 per tablet

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA205649
XIGDUO XR
Astrazeneca AbOctober 29, 2014 21, latest August 11, 2026
2026: Labeling · 2026: Labeling · 2024: Efficacy

Generic approvals (7)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.

  1. March 15, 2021 · Class II · Terminated · D-0436-2021

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

    xigduo XR (dapagliflozin/metformin HCl extended-release) tablets 5 mg/1000 mg 60 Tablets Rx only NDC 0310-6260-60 Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 — Cardinal Health Inc.

  2. March 15, 2021 · Class II · Terminated · D-0435-2021

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

    xigduo XR (dapgliflozin/metformin HCl extended-release) tablets 10 mg/1000 mg 30 Tablets Rx only NDC 0310-6280-30 Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 Manufactured by: Bristol-Myers Squib — Cardinal Health Inc.

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Official identifiers

RxCUI (RxNorm)1593058, 1593068, 1593070, 1593072, 1593775, 1593831, 1593833, 1593835, 1940496, 1940498
SPL set ID of the quoted labelac8a0f7b-9f69-4495-abbc-3a47cd75a859
FDA labels (SPL)10
FDA applicationsNDA205649, 7 ANDA
Active ingredients (FDA)DAPAGLIFLOZIN / METFORMIN

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Xigduo XR, AstraZeneca Pharmaceuticals LP, effective August 11, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers